CANCER AND LEUKEMIA GROUP B--CORRELATIVE SCIENCES

癌症和白血病 B 组——相关科学

基本信息

批准号：
2390656
负责人：
CLARA D BLOOMFIELD
金额：
$ 116.65万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1984
资助国家：
美国
起止时间：
1984-04-01 至 1998-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/2390656
关键词：
DNA binding protein RNase protection assay T cell receptor acute lymphocytic leukemia acute myelogenous leukemia aneuploidy angiogenesis azacitidine brca gene breast neoplasm /cancer diagnosis breast neoplasms cancer registry /resource cancer risk carcinogenesis cell cycle proteins chromosome deletion chromosome translocation chronic myelogenous leukemia clinical trials coagulation factor VIII collagenase combination cancer therapy combination chemotherapy cooperative study cyclophosphamide daunorubicin etoposide fibroblast growth factor flow cytometry gene expression gene mutation gene rearrangement genetic polymorphism human subject human therapy evaluation immunocytochemistry immunoglobulin genes immunologic assay /test loss of heterozygosity lymph node neoplasm lymphoma mitoxantrone monoclonal antibody mucins myeloproliferative neoplasm natural gene amplification neoplasm /cancer chemotherapy neoplasm /cancer classification /staging neoplasm /cancer epidemiology neoplasm /cancer genetics neoplasm /cancer immunology neoplasm /cancer relapse /recurrence neoplasm /cancer remission /regression nucleic acid sequence phenotype polymerase chain reaction prognosis proliferating cell nuclear antigen receptor expression tissue /cell culture tissue inhibitor of metalloproteinases tumor antigens tumor suppressor genes

项目摘要

The purpose of this grant is to support the CALGB Program in Correlative Sciences through support of the Correlative Sciences Committee Office at the Roswell Park Cancer Institute (RPCI) and the 10 Central Reference Laboratories or Facilities located at RPCI and 7 other Institutions. The primary objective of the proposed research is to evaluate the use of in vitro studies of the immunologic, cytogenetic and molecular genetic characteristics of leukemia, lymphoma and breast cancer cells to improve our ability to diagnose, classify, and treat these diseases in adults. The major specific aims of the current and proposed Correlative Sciences studies in leukemia are 1) to define the clinical significance of immunophenotype using multiparameter flow cytometry in adult AML and ALL, 2) to further define the clinical significance of chromosome analysis in adult AML, ALL, MDS, and CML, 3) to define the clinical and epidemiologic significance of RAS mutations in adult AML and MDS, 4) to define the incidence and clinical significance of loss of heterozygosity on chromosomes 5 and 7 in adult AML and MDS, 5) to further define the clinical significance of molecular analysis of the Philadelphia chromosome in ALL and CML, 6) to define the clinical significance of monitoring minimal residual disease (MRD) in adult ALL using an RNAse protection assay for tumor- specific rearrangements in T-cell receptor and immunoglobulin heavy chain genes, and 7) to develop a centralized tissue bank of tumor cells from patients with AML and ALL; in lymphoma, to determine 1) the clinical significance of monitoring MRD by PCR amplification of t(14;18) breakpoints in follicular small cleaved lymphoma, and 2) the clinical significance of monitoring MRD by RNAse protection assay for rearranged antigen receptor genes in intermediate grade lymphoma; in breast cancer (BrCa) to determine 1) the clinical significance of ploidy and S-phase activity in stage II BrCa, 2) the role of erb B2, p53, and cathepsin D overexpression, determined immunohistochemically, as prognostic and therapeutic markers, 3) the clinical significance of genetic abnormalities (amplification of HER-2 gene or the INT-2 locus, mutations in p53) in stage II BrCa, 4) the prognostic significance of staining of primary BrCa tissue with a monoclonal antibody to the core protein of DF3 mucin-like antigen, 5) by immunohistochemical study the prognostic significance in BrCa of expression of nm23 anti-metastatic marker, MMP-2, TIMP-2, and PCNA, 6) the prognostic significance of neo- angiogenesis in stage II primary BrCa tissue determined by staining for factor VIII, and 7) if elevated circulating or urinary levels of bFGF angiogenic factor predict clinical course in BrCa. These specific aims will be accomplished through 12 ongoing and 3 closed CALGB Studies, as well as 4 under development. The Correlative Sciences Committee is chaired by Clara D. Bloomfield, M.D. (RPCI). The Program is developed, coordinated, and administered through the Correlative Sciences Committee Offices at RPCI. The proposed research should increase our understanding of the biology, diagnosis, classification, and treatment of adults with leukemia, lymphoma, and BrCa.

这笔赠款的目的是支持Calgb计划相关科学通过支持相关科学罗斯威尔公园癌症研究所（RPCI）和委员会办公室位于RPCI和7的10个中央参考实验室或设施其他机构。拟议研究的主要目的是评估免疫学，细胞遗传学的体外研究的使用以及白血病，淋巴瘤和乳房的分子遗传特征癌细胞提高我们诊断，分类和治疗的能力这些疾病在成年人中。电流的主要具体目的拟议的白血病相关科学研究为1）定义使用多参数流的免疫表型的临床意义成人AML和全部的细胞仪，2）进一步定义临床染色体分析在成人AML，ALL，MDS和CML中的重要性， 3）定义RAS的临床和流行病学意义成人AML和MDS的突变，4）定义发病率和临床杂合性丧失对成人染色体5和7的显着性 AML和MDS，5）进一步定义费城染色体的分子分析和CML，6）定义监测最小残留的临床意义疾病（MRD）在成年人中使用RNase保护测定法进行肿瘤 - T细胞受体和免疫球蛋白沉重的特定重排链基因和7）开发肿瘤细胞的集中组织库来自AML和所有患者；在淋巴瘤中，确定1）通过PCR扩增监测MRD的临床意义 t（14; 18）卵泡小裂解淋巴瘤中的断点，2）通过RNase保护测定法监测MRD的临床意义中级淋巴瘤中重排的抗原受体基因；在乳腺癌（BRCA）确定1） II期BRCA中的倍性和S期活性，2）ERB B2的作用， p53和组织蛋白酶D过表达，以免疫组织化学确定作为预后和治疗标记，3）遗传异常（HER-2基因或INT-2基因座的扩增， p53中的突变）在II期BRCA中，4）用单克隆抗体染色原代BRCA组织 DF3粘蛋白样抗原的蛋白质，5）通过免疫组织化学研究 NM23抗中转移表达的BRCA的预后意义 Marker，MMP-2，TIMP-2和PCNA，6）新的预后意义通过染色确定的II期主要BRCA组织中的血管生成 VIII因子和7）如果BFGF的循环或尿液水平升高血管生成因子预测BRCA的临床过程。这些具体目标将通过12个正在进行的和3个封闭的Calgb研究来完成，正常开发4。相关科学委员会是由Clara D. Bloomfield（RPCI）主持。该程序是开发的，协调并通过相关科学管理 RPCI的委员会办公室。拟议的研究应增加我们的了解生物学，诊断，分类和治疗患有白血病，淋巴瘤和BRCA的成年人。

项目成果

期刊论文数量（11）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Prognostic value of lymphocyte surface markers in acute myeloid leukemia.

DOI：
10.1182/blood.v77.10.2242.2242
发表时间：
1991-05
期刊：
Blood
影响因子：
20.3
作者：
E. Ball;RB Davis;J. Griffin;R. J. Mayer;F. Davey;D. Arthur;D. Wurster‐Hill;W. Noll;M. Elgh
通讯作者：
E. Ball;RB Davis;J. Griffin;R. J. Mayer;F. Davey;D. Arthur;D. Wurster‐Hill;W. Noll;M. Elgh

Morphologic characteristics of acute lymphoblastic leukemia (ALL) with abnormalities of chromosome 8, band q24.

8号染色体q24带异常的急性淋巴细胞白血病（ALL）的形态学特征。

DOI：
10.1002/ajh.2830400306
发表时间：
1992
期刊：
American journal of hematology
影响因子：
12.8
作者：
Davey,FR;Lawrence,D;MacCallum,J;Varney,J;Hutchison,R;Wurster-Hill,D;Schiffer,C;Sobol,RE;Ciminelli,N;LeBeau,M
通讯作者：
LeBeau,M

Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.

针对新诊断的无先前血细胞减少症且患有法国-美国-英国标准定义的骨髓增生异常综合征的患者的急性髓性白血病型化疗：癌症和白血病 B 组研究。

DOI：
10.1200/jco.1996.14.9.2486
发表时间：
1996
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
0
作者：
Bernstein,SH;Brunetto,VL;Davey,FR;Wurster-Hill,D;Mayer,RJ;Stone,RM;Schiffer,CA;Bloomfield,CD
通讯作者：
Bloomfield,CD

The use of monoclonal antibodies against primary myeloid granules in normal and leukemic cells.

使用针对正常和白血病细胞中的原发性骨髓颗粒的单克隆抗体。

DOI：
10.1093/ajcp/98.4.430
发表时间：
1992
期刊：
American journal of clinical pathology
影响因子：
3.5
作者：
Elghetany,MT;Sullivan,AK;Kurec,AS;MacCallum,JM;Bloomfield,CD;Sobol,RE;Davey,FR
通讯作者：
Davey,FR

Chromosomal abnormalities in myelodysplastic syndromes and acute myeloid leukemia.

骨髓增生异常综合征和急性髓系白血病的染色体异常。